Application of palmitoyl carnitine in preparation of medicine for preventing and / or treating inflammatory bowel disease
By using palmitoyl carnitine to increase the proportion of Treg cells and reduce the proportion of inflammatory T cells, drugs to improve inflammatory bowel disease have been solved, and the problem of unutilized palmitoyl carnitine in the treatment of inflammatory bowel disease in the prior art has been achieved. Effective relief of inflammatory symptoms and the provision of new treatments.
Patent Information
- Application Number
- CN202411240344.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-05
AI Technical Summary
The existing drugs for treating inflammatory bowel disease have not yet effectively utilized palmitoyl carnitine, and the mechanism of action of its anti-inflammatory bowel disease has not been reported in literature, and new treatment methods or drugs are lacking.
Palmitoyl carnitine improves the symptoms of colitis by increasing the proportion of Treg cells in mesenteric lymph nodes, reducing the proportion of CD4+IL17+ and CD4+IFNγ+T cells, and improving the symptoms of colitis. It is used to prepare drugs to prevent and treat ulcerative colitis or Crohn's disease, and Can be used alone or in combination with other drugs.
Palmitoyl carnitine significantly improves the symptoms of colitis, reduces disease activity index, reduces inflammatory cell infiltration and submucosal edema, and has no obvious toxic side effects, providing a new low-cost treatment method.
Smart Images

Figure CN119033751A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, in particular to the application of palmitoyl carnitine in the preparation of medicines for preventing and / or treating inflammatory bowel disease. Background Art
[0002] Palmitoylcarnitine belongs to the acylcarnitine class of organic compounds and is a fatty acid lipid molecule. As an important intermediate in the mitochondrial fatty acid oxidation process, palmitoylcarnitine can promote fatty acid oxidation metabolism, improve the body's energy utilization, and reduce body fat accumulation. In addition, palmitoylcarnitine can also promote muscle growth and repair, and improve the body's athletic ability and endurance.
[0003] Inflammatory bowel disease is a chronic, nonspecific intestinal inflammatory disease, mainly including ulcerative colitis and Crohn's disease. Among them, ulcerative colitis is a chronic inflammatory disease, the cause of which is still unclear, and may be related to multiple factors such as genetics, immunity, and infection. Currently, the main drugs used in clinical treatment of inflammatory bowel disease are salicylates, glucocorticoids, and immunosuppressants, etc. These drugs are mainly used to reduce inflammation, inhibit immune response, and alleviate the condition.
[0004] However, there is no literature report on the anti-inflammatory bowel disease activity and mechanism of action of palmitoylcarnitine. Summary of the invention
[0005] The purpose of the present invention is to provide the use of palmitoyl carnitine in the preparation of a drug for preventing and / or treating inflammatory bowel disease, aiming to expand the clinical application range of palmitoyl carnitine and provide a new treatment method or drug for the treatment or prevention of inflammatory bowel disease.
[0006] In order to achieve the above object, the first aspect of the present invention provides the use of palmitoyl carnitine in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.
[0007] Furthermore, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
[0008] Furthermore, in the drug for preventing and / or treating inflammatory bowel disease, palmitoyl carnitine improves the symptoms of colon shortening, disease activity index, inflammatory cell infiltration, submucosal edema and crypt cysts caused by colitis; palmitoyl carnitine comprehensively improves the symptoms of colitis by increasing the proportion of Treg cells in mesenteric lymph nodes and reducing the proportion of CD4+IL17+T cells and CD4+IFNγ+T cells in mesenteric lymph nodes.
[0009] Furthermore, the drug for preventing and / or treating inflammatory bowel disease uses palmitoyl carnitine as the only active monomer component, or palmitoyl carnitine is used in combination with other drugs to form a pharmaceutical composition.
[0010] Furthermore, the drug for preventing and / or treating inflammatory bowel disease also includes pharmaceutically acceptable excipients, such as any one or more of diluents, adhesives, lubricants, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, antioxidants, antibacterial agents, and buffers.
[0011] Furthermore, the dosage form of the drug for preventing and / or treating inflammatory bowel disease is any one or more of suspension, granules, capsules, tablets, powders, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.
[0012] Furthermore, the administration route of the drug for preventing and / or treating inflammatory bowel disease is any one or more of oral administration, intravenous administration, intraperitoneal injection, intramuscular injection, subcutaneous injection, sublingual administration, transdermal administration or rectal suppository administration.
[0013] Furthermore, in the drug for preventing and / or treating inflammatory bowel disease, the dosage of palmitoyl carnitine is 4 mg / kg / day.
[0014] The second aspect of the present invention provides a drug for preventing and / or treating inflammatory bowel disease, wherein the drug contains palmitoyl carnitine as the only active monomer component, or palmitoyl carnitine is used in combination with other drugs to form a pharmaceutical composition.
[0015] The advantages of the present invention are:
[0016] The palmitoyl carnitine involved in the present invention has low preparation cost and no obvious toxic side effects. Animal experiments have shown that palmitoyl carnitine can improve the symptoms of colitis by increasing the cell ratio of regulatory T cells (Treg) in mesenteric lymph nodes and reducing the ratio of CD4+IL17+T cells and CD4+IFNγ+T cells in mesenteric lymph nodes, and can be used to prepare drugs for preventing and / or treating inflammatory bowel disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Schematic diagram of the colon length of each group of mice (from left to right: control group, DSS group, DSS+Pal group; the results shown in the figure are mean±SEM, n=5).
[0018] Figure 2Schematic diagram of the disease activity index of each group of mice (the horizontal axis represents the number of treatment days, the vertical axis represents the disease activity index; * represents compared with the control group, # represents compared with the model group; the results shown in the figure are mean ± SEM, n = 5).
[0019] Figure 3 Schematic diagram of HE staining of colon sections of mice in each group (from left to right: control group, DSS group, DSS+Pal group; magnification: 200 times).
[0020] Figure 4 Schematic diagram of the proportion of CD4+FOXP3+Treg cells in the mesenteric lymph nodes of each group of mice (from left to right: control group, DSS group, DSS+Pal group; the results shown in the figure are mean ± SEM, n = 5).
[0021] Figure 5 Schematic diagram of the proportion of CD4+IL17+T cells in the mesenteric lymph nodes of mice in each group (from left to right: control group, DSS group, DSS+Pal group; the results shown in the figure are mean ± SEM, n = 5).
[0022] Figure 6 Schematic diagram of the proportion of CD4+IFNγ+T cells in the mesenteric lymph nodes of mice in each group (from left to right: control group, DSS group, DSS+Pal group; the results shown in the figure are mean±SEM, n=5). DETAILED DESCRIPTION
[0023] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.
[0024] Example:
[0025] 1. Experimental Materials
[0026] Fifteen C57 / BL6 mice (male, 8 weeks old) were purchased from Shanghai Bio-Tech Biotechnology Co., Ltd.
[0027] Palmitoylcarnitine was purchased from Taoshu Biotechnology Co., Ltd. (T37299).
[0028] Dextran sulfate sodium salt (DSS) was purchased from Shanghai Yisheng Biotechnology Co., Ltd.
[0029] 2. Experimental Grouping
[0030] The mice were randomly divided into 3 groups according to their body weight, with 5 mice in each group, namely blank control group, model group and experimental group.
[0031] 3. Experimental Methods
[0032] 3.1 Administration method of model establishment agent
[0033] Blank control group (Ctrl): free access to water, and intragastric administration of sterile drinking water every day.
[0034] Model group (DSS group): The mice were allowed to drink freely the drinking water containing DSS (2.5% w / v) for 8 days.
[0035] Experimental group (Pal group): The mice were allowed to drink freely the drinking water containing DSS (2.5% w / v) for 8 days, and palmitoyl carnitine (4 mg / kg / day) was administered intragastrically every day.
[0036] 3.2 The mice were weighed and fecal occult blood was tested and recorded every day, and scored according to the DAI scoring table (Table 1). The average score of the three items was the Disease Activity Index (DAI).
[0037] Table 1. DAI scoring criteria
[0038] score Percentage of weight loss Stool consistency Fecal occult blood 0 0 standard Negative 1 1~5 Soft but moldable Negative 2 6~10 Soft and shapeless Positive 3 11~20 Very soft and moist Visible blood in stool 4 >20 Watery diarrhea Heavy rectal bleeding
[0039] 3.3 On the 8th day of the experiment, the mice were killed by cervical dislocation, serum was collected, the colon was measured and its length was recorded, and the colon sections were HE stained; the mesenteric lymph nodes of the mice were collected, and the proportion of CD4+IL17+T cells and CD4+IFNγ+T cells were detected by flow cytometry.
[0040] 4. Experimental Results
[0041] 4.1 Palmitoylcarnitine improves colitis symptoms in mice
[0042] The colon length of each group of mice was Figure 1 shown. Figure 1 Schematic diagram of colon length in each group. Figure 1 It can be seen that compared with the control group, the colon length of the model group mice was shortened (P < 0.001), while the colon length of the palmitoyl carnitine-treated group was significantly longer than that of the model group (P < 0.01), indicating that palmitoyl carnitine significantly improved the symptoms of colon shortening caused by colitis in mice.
[0043] The disease activity index of each group of mice was Figure 2 As shown. Figure 2 It can be seen that compared with the control group, the disease activity index of mice in the model group was increased, and the difference was statistically significant from the fourth day (P < 0.05). The disease activity index of the palmitoylcarnitine group was lower than that of the model group, and the difference was statistically significant from the fifth day (P < 0.05).
[0044] HE staining of colon sections of mice in each group is shown in Figure 3 As shown. Figure 3It can be seen that the model group showed abnormal changes in mucosal epithelial morphology, inflammatory cell infiltration, submucosal edema, and crypt cysts, while the palmitoylcarnitine group showed significant improvement compared with the model group.
[0045] Figures 1 to 3 The results showed that the model group was successfully established and the colitis symptoms in the experimental group were alleviated, indicating that palmitoyl carnitine can improve the colitis symptoms in model mice.
[0046] 4.2 Palmitoylcarnitine increases the proportion of Treg cells in mouse mesenteric lymph nodes
[0047] The ratio of Treg cells in the intestinal lymph nodes of each group of mice was as follows Figure 4 As shown. Figure 4 It can be seen that the proportion of CD4+FOXP3+T cells in the model was significantly reduced (P<0.05), while the proportion of CD4+FOXP3+T cells in the palmitoylcarnitine gavage treatment group was increased (P<0.01).
[0048] 4.3 Palmitoylcarnitine reduces the proportion of CD4+IL17+T cells in the mesenteric lymph nodes of mice
[0049] The ratio of CD4+IL17+T cells in the intestinal lymph nodes of each group of mice Figure 5 As shown. Figure 5 It can be seen that the proportion of CD4+IL17+T cells in the model group was significantly increased (P<0.01), while the proportion of CD4+IL17+T cells in the palmitoyl carnitine gavage treatment group was decreased (P<0.05).
[0050] 4.4 Palmitoylcarnitine reduces the proportion of CD4+IFNγ+T cells in the mesenteric lymph nodes of mice
[0051] The ratio of CD4+IFNγ+T cells in the intestinal lymph nodes of each group of mice Figure 6 As shown. Figure 6 It can be seen that the proportion of CD4+IFNγ+T cells in the model group was significantly increased (P<0.05), while the proportion of CD4+IFNγ+T cells in the palmitoyl gavage treatment group was decreased (P<0.05).
[0052] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. Use of palmitoyl carnitine in preparing a drug for preventing and / or treating inflammatory bowel disease.
2. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The inflammatory bowel disease is ulcerative colitis or Crohn's disease.
3. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: In the drug for preventing and / or treating inflammatory bowel disease, palmitoyl carnitine improves the symptoms of colon shortening, disease activity index, inflammatory cell infiltration, submucosal edema and crypt cysts caused by colitis.
4. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: Palmitoyl carnitine comprehensively improves colitis symptoms by increasing the proportion of Treg cells in mesenteric lymph nodes and reducing the proportion of CD4+IL17+T cells and CD4+IFNγ+T cells in mesenteric lymph nodes.
5. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The drug for preventing and / or treating inflammatory bowel disease uses palmitoyl carnitine as the only active monomer component, or palmitoyl carnitine is used in combination with other drugs to form a drug composition.
6. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The drug for preventing and / or treating inflammatory bowel disease also includes pharmaceutically acceptable excipients.
7. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The dosage form of the drug for preventing and / or treating inflammatory bowel disease is any one or more of suspension, granules, capsules, tablets, powders, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.
8. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The administration route of the drug for preventing and / or treating inflammatory bowel disease is any one or more of oral administration, intravenous administration, intraperitoneal injection, intramuscular injection, subcutaneous injection, sublingual administration, transdermal administration or rectal suppository administration.
9. The use of palmitoyl carnitine according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: In the drug for preventing and / or treating inflammatory bowel disease, the dosage of palmitoyl carnitine is 4 mg / kg / day.
10. A drug for preventing and / or treating inflammatory bowel disease, characterized in that: The medicine uses palmitoyl carnitine as the only active monomer component, or palmitoyl carnitine is used in combination with other medicines to form a medicine composition.
Citation Information
Patent Citations
Pharmaceutical application of palmitoyl carnitine
CN117982482A
Therapeutic application of acetyl-d,l-carnitine and other acyl derivatives of d,l-carnitine
US4194006A
Use of alkanoyl L-carnitines for the therapeutical treatment of chronic inflammatory bowel diseases
US6013670A
Complexes of hyaluronic acid / carnitines and pharmaceutical and cosmetic compositions
US6585987B1
Methods of trea fing ??d methods of diagnosing an immunoproliferative disorder
WO2010008852A2
